11,129 LeMaitre Vascular, Inc. $LMAT Shares Bought by Riverbridge Partners LLC

Riverbridge Partners LLC raised its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 12.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 99,596 shares of the medical instruments supplier’s stock after buying an additional 11,129 shares during the period. Riverbridge Partners LLC owned about 0.44% of LeMaitre Vascular worth $8,226,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Summit Creek Advisors LLC lifted its holdings in LeMaitre Vascular by 0.9% in the third quarter. Summit Creek Advisors LLC now owns 49,624 shares of the medical instruments supplier’s stock valued at $4,098,000 after acquiring an additional 450 shares during the period. Kornitzer Capital Management Inc. KS boosted its position in LeMaitre Vascular by 11.0% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 13,650 shares of the medical instruments supplier’s stock worth $1,127,000 after purchasing an additional 1,352 shares in the last quarter. Boston Trust Walden Corp acquired a new stake in shares of LeMaitre Vascular during the 3rd quarter worth approximately $28,546,000. Bridge City Capital LLC grew its stake in shares of LeMaitre Vascular by 35.5% during the 3rd quarter. Bridge City Capital LLC now owns 116,980 shares of the medical instruments supplier’s stock worth $9,661,000 after purchasing an additional 30,639 shares during the period. Finally, ProShare Advisors LLC grew its stake in shares of LeMaitre Vascular by 36.2% during the 3rd quarter. ProShare Advisors LLC now owns 102,571 shares of the medical instruments supplier’s stock worth $8,471,000 after purchasing an additional 27,270 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several analyst reports. Wells Fargo & Company decreased their target price on shares of LeMaitre Vascular from $94.00 to $86.00 and set an “equal weight” rating for the company in a research note on Thursday, November 5th. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Thursday, November 5th. Citizens Jmp started coverage on shares of LeMaitre Vascular in a report on Thursday, November 5th. They issued a “market outperform” rating and a $110.00 price objective for the company. Finally, Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 23rd. Three investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $108.25.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $79.02 on Wednesday. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of 29.51, a PEG ratio of 2.39 and a beta of 0.51. The stock has a 50-day moving average of $81.47 and a 200 day moving average of $94.05. The company has a current ratio of 14.60, a quick ratio of 12.54 and a debt-to-equity ratio of 0.39. LeMaitre Vascular, Inc. has a twelve month low of $78.22 and a twelve month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $0.65 EPS for the quarter, missing the consensus estimate of $0.69 by ($0.04). The business had revenue of $67.97 million during the quarter, compared to analyst estimates of $67.39 million. LeMaitre Vascular had a net margin of 23.51% and a return on equity of 15.33%. The firm’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.75 earnings per share. Sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 2.83 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Thursday, November 19th will be given a dividend of $0.25 per share. The ex-dividend date is Thursday, November 19th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.3%. LeMaitre Vascular’s dividend payout ratio (DPR) is 36.36%.

LeMaitre Vascular Profile

LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.